DE602006015180D1 - Rekombinanter Mycobakteriumstamm, der ein FAP Protein aus Mycobakterium unter der Kontrolle eines Promotors, der unter hypoxischen Konditionen aktiv ist, exprimiert, und dessen Verwendung zur Tumortherapie - Google Patents

Rekombinanter Mycobakteriumstamm, der ein FAP Protein aus Mycobakterium unter der Kontrolle eines Promotors, der unter hypoxischen Konditionen aktiv ist, exprimiert, und dessen Verwendung zur Tumortherapie

Info

Publication number
DE602006015180D1
DE602006015180D1 DE602006015180T DE602006015180T DE602006015180D1 DE 602006015180 D1 DE602006015180 D1 DE 602006015180D1 DE 602006015180 T DE602006015180 T DE 602006015180T DE 602006015180 T DE602006015180 T DE 602006015180T DE 602006015180 D1 DE602006015180 D1 DE 602006015180D1
Authority
DE
Germany
Prior art keywords
mycobacterium
promoter active
control
hypoxic conditions
tumor therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006015180T
Other languages
English (en)
Inventor
Gilles Marchal
Mohammad Abolhassani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur de Lille
Original Assignee
Institut Pasteur de Lille
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur de Lille filed Critical Institut Pasteur de Lille
Publication of DE602006015180D1 publication Critical patent/DE602006015180D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DE602006015180T 2006-07-25 2006-07-25 Rekombinanter Mycobakteriumstamm, der ein FAP Protein aus Mycobakterium unter der Kontrolle eines Promotors, der unter hypoxischen Konditionen aktiv ist, exprimiert, und dessen Verwendung zur Tumortherapie Active DE602006015180D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06291205A EP1882741B1 (de) 2006-07-25 2006-07-25 Rekombinanter Mycobakteriumstamm, der ein FAP Protein aus Mycobakterium unter der Kontrolle eines Promotors, der unter hypoxischen Konditionen aktiv ist, exprimiert, und dessen Verwendung zur Tumortherapie

Publications (1)

Publication Number Publication Date
DE602006015180D1 true DE602006015180D1 (de) 2010-08-12

Family

ID=37026080

Family Applications (2)

Application Number Title Priority Date Filing Date
DE602006015180T Active DE602006015180D1 (de) 2006-07-25 2006-07-25 Rekombinanter Mycobakteriumstamm, der ein FAP Protein aus Mycobakterium unter der Kontrolle eines Promotors, der unter hypoxischen Konditionen aktiv ist, exprimiert, und dessen Verwendung zur Tumortherapie
DE602007013248T Active DE602007013248D1 (de) 2006-07-25 2007-07-25 Rekombinanter mycobakterienstamm zur durch einen bei hypoxie aktiven promotor gesteuerten expression eines mykobakteriellen fap-proteins und seine anwendung zur krebstherapie

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE602007013248T Active DE602007013248D1 (de) 2006-07-25 2007-07-25 Rekombinanter mycobakterienstamm zur durch einen bei hypoxie aktiven promotor gesteuerten expression eines mykobakteriellen fap-proteins und seine anwendung zur krebstherapie

Country Status (10)

Country Link
US (2) US20090304637A1 (de)
EP (2) EP1882741B1 (de)
JP (1) JP2009544305A (de)
AT (2) ATE472602T1 (de)
CA (1) CA2658713A1 (de)
DE (2) DE602006015180D1 (de)
DK (1) DK1882741T3 (de)
ES (1) ES2347812T3 (de)
HK (1) HK1112753A1 (de)
WO (1) WO2008012693A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008140598A2 (en) * 2006-12-04 2008-11-20 Bacilligen, Inc. Novel immunotherapeutic mycobacteria, pharmaceutic formulations and uses thereof
EP2620159A1 (de) 2012-01-24 2013-07-31 Institut Pasteur Verbesserte Krebsbehandlung durch Immuntherapie mit BCG- oder antigenetisch ähnlichen nicht-pathogenen Mykobakterien
EP2882461A4 (de) * 2012-08-10 2016-08-17 Sloan Kettering Inst Cancer Vorhersage der blasenkrebsreaktion auf bcg
US10494665B2 (en) * 2014-08-20 2019-12-03 Huawei Yang Test kit and method for testing target nucleic acid in sample
WO2018111989A1 (en) 2016-12-14 2018-06-21 Purdue Research Foundation Fibroblast activation protein (fap)-targeted imaging and therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6599510B1 (en) * 1993-11-23 2003-07-29 The Regents Of The University Of California Abundant extracellular products and methods for their production and use
US5834306A (en) * 1994-12-23 1998-11-10 Sri International Tissue specific hypoxia regulated therapeutic constructs
AU3593200A (en) * 1999-02-09 2000-08-29 Powderject Vaccines, Inc. (mycobacterium tuberculosis), immunization
WO2004006952A2 (en) * 2002-07-13 2004-01-22 Statens Serum Institut Therapeutic tuberculosis vaccines
WO2005037222A2 (en) * 2003-10-16 2005-04-28 The Regents Of The University Of California Recombinant intracellular pathogen immunogenic compositions and methods for use
DE602004028506D1 (de) * 2003-12-02 2010-09-16 Pasteur Institut Neuer mit sars verbunden coronavirus stamm und seine verwendungen

Also Published As

Publication number Publication date
ATE472602T1 (de) 2010-07-15
DE602007013248D1 (de) 2011-04-28
JP2009544305A (ja) 2009-12-17
WO2008012693A2 (en) 2008-01-31
EP2049667A2 (de) 2009-04-22
US20120156169A1 (en) 2012-06-21
EP1882741A1 (de) 2008-01-30
HK1112753A1 (en) 2008-09-12
CA2658713A1 (en) 2008-01-31
US20090304637A1 (en) 2009-12-10
ATE502110T1 (de) 2011-04-15
EP1882741B1 (de) 2010-06-30
WO2008012693A3 (en) 2008-04-24
EP2049667B1 (de) 2011-03-16
DK1882741T3 (da) 2010-10-11
ES2347812T3 (es) 2010-11-04

Similar Documents

Publication Publication Date Title
UA99452C2 (ru) Способ стимулирования миелинизации и дифференцирования олигодендроцитов путем применения семафорина 6a
DE602006015180D1 (de) Rekombinanter Mycobakteriumstamm, der ein FAP Protein aus Mycobakterium unter der Kontrolle eines Promotors, der unter hypoxischen Konditionen aktiv ist, exprimiert, und dessen Verwendung zur Tumortherapie
EA201101037A1 (ru) Лечение диабета у пациентов с неадекватным гликемическим контролем, несмотря на лечение метформином
DE602006006068D1 (de) Verwendung von botulintoxin zur verbesserung der magenentleerung und/oder behandlung von gerd
TN2014000224A1 (en) Glucagon analogues
NZ562436A (en) Toll-like receptor 14 (TLR14) and use thereof
MX361259B (es) Uso de un fragmento de peptido hmgb1 para el tratamiento del infarto al miocardio.
ES2675375T3 (es) Anticuerpos monoclonales contra claudina 18 para el tratamiento del cáncer
HUE049880T2 (hu) Anyag és eljárások Her-3-mal összefüggõ betegségek kezelésére vagy megelõzésére
WO2007143090A3 (en) Hepatocyte growth factor (hgf) binding proteins
MX359201B (es) Polipeptidos que se unen al complemento humano 5 (c5).
WO2010132389A3 (en) Methods for treating cancers and diseases associated with 4-1bb (cd137) expression
UA106458C2 (uk) Чутливий до сульфонілсечовини репресорний білок
NZ588435A (en) Use of a polypeptide with an angiotensin-converting enzyme 2 (ACE2) activity for treating tumours (with the exception of lung cancer)
PL2005185T3 (pl) Sposoby identyfikowania celów polipeptydowych
WO2011082382A3 (en) Methods for detecting and regulating alopecia areata and gene cohorts thereof
EP1790720A4 (de) Polypeptid mit der aktivität einer ungesättigten omega-3-fettsäure, für das polypeptid codierendes polynukleotid und verwendung davon
MX2009008135A (es) Uso de histidinato de cromo para tratamiento de alteraciones cardiometabolicas.
SG165386A1 (en) Novel physiological substance nesfatin, substance relevant thereto, and use of the substances
MX2015005253A (es) Metodo novedoso para tratar el daño a la medula espinal utilizando el fragmento de hmgb1.
MX2014013950A (es) Antagonistas de proteina que interactua con el receptor nogo 2 que contiene repeticion rica en leucina y dominio de inmunoglobulina (lingo-2) para el tratamiento de afecciones que involucran neuronas motoras.
EP2362904A4 (de) Verfahren zur behandlung oder vorbeugung von blasenkrebs unter verwendung des depdc1-polypeptids
WO2008047235A3 (en) Methods of treating disorders associated with fat storage
WO2008005487A3 (en) Peptide sequences for modulation of protein kinase c
EP1988915A4 (de) Verfahren zur modulierung der zellaktivität und mittel zur verwendung damit